Printza Athanasia, Boziki Marina, Valsamidis Constantinos, Bakirtzis Christos, Constantinidis Jannis, Grigoriadis Nikolaos, Triaridis Stefanos
1st Otolaryngology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital, 54124 Thessaloniki, Greece.
2nd Neurology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital, 54124 Thessaloniki, Greece.
J Clin Med. 2022 Sep 3;11(17):5215. doi: 10.3390/jcm11175215.
Existing data suggest that people with multiple sclerosis (pwMS) are at an elevated risk for experiencing olfactory impairment. We investigated if smell dysfunction can be used as an MS disease marker. This is a cross-sectional, case−control study. All data were collected prospectively from 171 participants, 115 pwMS and 56 controls (age and sex stratified and matched to the patients), who reported smell, taste, and nasal breathing, and completed the Greek-validated questionnaires for nasal obstruction (NOSE), nasal-symptoms QoL (SNOT-22), and olfaction-associated QoL (QOD). The smell was assessed with the “Sniffin’ sticks” (odor threshold (OT), discrimination (OD), identification (OI) test, and total TDI). We recorded the pwMS disease characteristics (Expanded Disability Status Scale-EDSS, the disease type and duration), cognitive function, emotional status, fatigue, and impact of MS in everyday activities. A TDI < 30.75 (hyposmia) was detected in 30.8% of the patients. The patients’ OD and TDI scores were significantly lower than the controls’ (p = 0.005, and 0.015, respectively). The hyposmia correlated with disease severity and duration. The EDSS score correlated negatively with OD (r = −0.299, p = 0.001) and TDI (r = −0.242, p = 0.01). The disease duration correlated negatively with OD (r = −0.305, p = 0.001, OI (r = −0.253, p = 0.008) and TDI (r = −0.3, p = 0.001). The information processing speed (SDMT) correlated with OD, OT, and TDI (r = 0.302, p = 0.002; r = 0.242, p = 0.016; r = 0.326, p = 0.001). The olfactory function is changing in MS in accordance with disease progression.
现有数据表明,多发性硬化症患者(pwMS)出现嗅觉障碍的风险较高。我们研究了嗅觉功能障碍是否可作为多发性硬化症的疾病标志物。这是一项横断面病例对照研究。所有数据均前瞻性收集自171名参与者,其中115名pwMS患者和56名对照者(按年龄和性别分层并与患者匹配),他们报告了嗅觉、味觉和鼻腔呼吸情况,并完成了希腊语验证的鼻塞问卷(NOSE)、鼻部症状生活质量问卷(SNOT - 22)和嗅觉相关生活质量问卷(QOD)。使用“嗅觉棒”评估嗅觉(气味阈值(OT)、辨别力(OD)、识别力(OI)测试以及总TDI)。我们记录了pwMS患者的疾病特征(扩展残疾状态量表 - EDSS、疾病类型和病程)、认知功能、情绪状态、疲劳程度以及MS对日常活动的影响。30.8%的患者检测出TDI < 30.75(嗅觉减退)。患者的OD和TDI得分显著低于对照组(分别为p = 0.005和0.015)。嗅觉减退与疾病严重程度和病程相关。EDSS评分与OD呈负相关(r = - 0.299,p = 0.001)和TDI呈负相关(r = - 0.242,p = 0.01)。病程与OD呈负相关(r = - 0.305,p = 0.001)、OI呈负相关(r = - 0.253,p = 0.008)和TDI呈负相关(r = - 0.3,p = 0.001)。信息处理速度(SDMT)与OD、OT和TDI相关(r = 0.302,p = 0.002;r = 0.242,p = 0.016;r = 0.326,p = 0.001)。在多发性硬化症中,嗅觉功能随疾病进展而变化。